SCHEMBL6490572

SCHEMBL6490572

CCOC(=O)COc1ccc(S(=O)(=O)Cl)c(C)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 4/20 0.57
NPSR1 Q6W5P4 2/20 0.57
KDM4E B2RXH2 3/20 0.51
HSD17B10 Q99714 3/20 0.51
HPGD P15428 5/20 0.47
POLB P06746 1/20 0.47
ALDH1A1 P00352 3/20 0.46
CASP1 P29466 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
MAPT P10636 3/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
MCL1 Q07820 2/20 0.46
MEN1 O00255 1/20 0.46
PKM P14618 1/20 0.46
KMT2A Q03164 1/20 0.46
PPARG P37231 1/20 0.45
PPARA Q07869 1/20 0.45
LMNA P02545 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8663968 0.85 GAA (0.53) GAANPSR1KDM4EHSD17B10HPGD
SCHEMBL9659543 0.84 PDIA6 (0.53) GAAKDM4EHSD17B10HPGDPOLB
SCHEMBL17973242 0.80 MCL1 (0.69) GAANPSR1KDM4EHSD17B10POLB
SCHEMBL2346864 0.80 GAA (0.77) GAANPSR1KDM4EHSD17B10HPGD
SCHEMBL1417326 0.79 KDM4E (0.44) GAANPSR1KDM4EHSD17B10HPGD
SCHEMBL2037512 0.78 HPGD (0.59) GAANPSR1KDM4EHSD17B10HPGD
SCHEMBL7372648 0.78 GAA (0.57) GAANPSR1KDM4EHSD17B10HPGD
SCHEMBL5324560 0.77 GAA (0.53) GAANPSR1KDM4EHSD17B10HPGD
SCHEMBL13744660 0.77 GAA (0.56) GAANPSR1KDM4EHSD17B10HPGD
SCHEMBL1257644 0.77 KDM4E (0.56) GAANPSR1KDM4EHSD17B10HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050234096-A1 Tetrahydroisoquinoline derivatives BAYER HEALTHCARE AG (DE) 2005-10-20 US disclosed
US-6887880-B2 Adenine based inhibitors of adenylyl cyclase, pharmaceutical compositions, and method of use thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-05-03 US disclosed
US-20020068745-A1 Adenine based inhibitors of adenylyl cyclase, pharmaceutical compositions, and method of use thereof MILLENNIUM PHARMACEUTICALS, INC. 2002-06-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020068745-A1 Adenine based inhibitors of adenylyl cyclase, pharmaceutical compositions, and method of use thereof CD38, ADCY1, ADCY2 GAA 2037/4885NPSR1 3098/4885KDM4E 2846/4885
US-20050234096-A1 Tetrahydroisoquinoline derivatives PPARD, PPARG, PPARA GAA 2179/4885NPSR1 2104/4885KDM4E 2915/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.